Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open in the green
Fri, 22 May 09:30 am

Indian markets have opened in green amid strong global cues. BSE Sensex and NSE-Nifty are trading with moderate gains of 0.2% each. Sectoral indices are trading on a mixed note with oil & gas and FMCG being the leading gainers while IT and power stocks were leading the losses. BSE Mid Cap and BSE Small Cap were up 0.4% and 0.3%, respectively.

Asian stock markets have opened on a positive note with markets in Hong Kong and Taiwan leading the charts. Meanwhile, stocks closed modestly higher in the US. Europe too witnessed equities finishing largely higher as investors grasped fresh data from the Euro zone. The Indian rupee opened with marginal gain of 6 paise at 63.58 per dollar on Friday against previous close of 63.64.

According to a leading financial daily, Idea Cellular, part of the Aditya Birla Group, is working on a Rs 75.8 bn deal to sell its independent towers, drawing the interests of Malaysia's Axiata, Bharti Infratel and American Tower Corporation. India's third largest mobile service provider owns and operates about 11,000 towers in the country. Reportedly, after the expensive spectrum auctions, Idea Cellular have been seeking fresh capital-raising plans. The company carries a consolidated debt of Rs 140 bn in FY15. The firm also raised Rs 30 bn through a qualified institutional placement process last year. The stock has opened the day on an optimistic note.

The stock of Glenmark Pharma has opened in green after it was reported that the company has been granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome. Rufinamide is a therapeutic equivalent of Banzel tablets of Eisai. Reportedly, for the 12 month period ending March, the Banzel market achieved annual sales of approximately US$121.8 million. Glenmark's current portfolio consists of 96 products authorized for distribution in the US marketplace and 68 ANDAs (Abbreviated New Drug Application) pending approval with the FDA.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in the green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.